Excellent quality and fast dispatch
Products arrived well-packaged with COA documentation included. Really appreciate the clear research-only labelling — exactly what I needed for my lab work.
James R.
Sydney, AU
Dual GIP/GLP-1 Receptor Agonist
Tirzepatide Australia
Everything researchers need to know about Tirzepatide — mechanism, published dosing protocols, side effect profiles, reconstitution, and how to source third-party tested Tirzepatide in Australia.
Quick facts
- Also known as: Dual GIP/GLP-1 Receptor Agonist (Mounjaro analogue)
- Form: Lyophilised powder (>99% purity)
- Variants: 5 mg, 10 mg, 15 mg
- 🇦🇺 3–5 business days
March 2025
Best local supplier I've found
Ordered three times now. HPLC verification results have been consistent each time. The pathway browsing structure makes it much easier to compare compounds.
Sarah K.
Melbourne, AU
Fast shipping, great documentation
Same-day dispatch on my last two orders. The batch COA was easy to locate and the product information pages are genuinely useful for research planning.
Michael T.
Brisbane, AU
Representative of verified researcher feedback.
Overview
What Is Tirzepatide?
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It represents a first-in-class approach to metabolic research by targeting two incretin receptors simultaneously. Research interest has surged due to its unique dual-agonist mechanism.
Also known as Dual GIP/GLP-1 Receptor Agonist (Mounjaro analogue), Tirzepatide is supplied as a lyophilised research peptide for laboratory use only. Studies show Tirzepatide activates both GIP and GLP-1 receptors, producing synergistic effects on metabolic parameters. Preclinical data demonstrates superior glycaemic control and body weight reduction compared to selective GLP-1 agonists alone. Its pharmacokinetic profile supports once-weekly research dosing protocols.
Mechanism
How Tirzepatide Works — Research Mechanism
Studies show Tirzepatide activates both GIP and GLP-1 receptors, producing synergistic effects on metabolic parameters. Preclinical data demonstrates superior glycaemic control and body weight reduction compared to selective GLP-1 agonists alone. Its pharmacokinetic profile supports once-weekly research dosing protocols.
- Simultaneous GIP and GLP-1 receptor activation
- Synergistic metabolic effects beyond single GLP-1 agonism
- Enhanced insulin sensitivity via GIP receptor signalling
- Once-weekly pharmacokinetic profile in published research
- First-in-class dual incretin research compound
Research reference
Tirzepatide Dosage — Published Research Protocols
The following reference points are drawn from published research literature. These figures are provided for research reference only and do not constitute dosing recommendations. Tirzepatide is sold strictly for laboratory research use.
| Protocol tier | Published research detail |
|---|---|
| SURPASS trial range | 2.5 mg to 15 mg weekly subcutaneous in published clinical research |
| Initiation dose | 2.5 mg weekly for 4 weeks before escalation |
| Mid-range | 5–10 mg weekly — dose-response metabolic studies |
| Maximum published dose | 15 mg weekly in Phase 3 trial cohorts |
| Available vials | 5 mg, 10 mg, and 15 mg lyophilised research vials |
Research use only: FOR LABORATORY RESEARCH USE ONLY. Not for human consumption, injection, or therapeutic use. All products are sold strictly as research chemicals. By purchasing, you confirm you are 18+ and agree to use products solely for legitimate research purposes.
Safety research
Tirzepatide Side Effects — Research Findings
Side effect profiles documented in published Tirzepatide research depend on dose, route of administration, and model system. The following are commonly reported findings from research literature — not from personal use contexts.
- Gastrointestinal effects (nausea, vomiting, diarrhoea) commonly reported in incretin-class research
- Injection site reactions at subcutaneous administration sites
- Appetite suppression observed dose-dependently in metabolic research models
- Most events in published trials reported as mild to moderate and dose-dependent
Handling
Reconstituting Tirzepatide
Tirzepatide is supplied as a lyophilised powder and must be reconstituted before use in laboratory protocols. Use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials. Inject diluent slowly down the inside wall of the vial — do not shake vigorously.
Bacteriostatic water is available from EvoPeak. Store reconstituted peptide at 2–8°C and lyophilised powder at −20°C.
Shop bacteriostatic waterAustralia
How to Get Tirzepatide in Australia
Researchers in Australia can source Tirzepatide through EvoPeak — a local supplier offering third-party tested research compounds with batch-specific COA documentation and domestic shipping.
- 1
Browse Tirzepatide variants (5 mg, 10 mg, 15 mg) on the EvoPeak product page
- 2
Review the certificate of analysis (COA) for HPLC purity and mass spectrometry identity verification
- 3
Select your vial size and add to cart — prices include GST with same-day Australian dispatch
- 4
Receive your order with batch-specific quality documentation for laboratory traceability
Quality Standard
Research compounds need evidence, not guesswork.
Every shopping path leads back to the same core standard: research-use positioning, third-party quality signals, transparent documentation, and careful handling guidance.
HPLC/MS verified
Purity and identity checks support confident compound selection for controlled research.
Endotoxin screened
Quality review extends beyond purity so researchers can evaluate handling risk.
Batch documentation
COA-first product pages keep quality signals close to every purchase decision.
Australia shipped
Local fulfilment keeps delivery predictable for Australian research customers.
Further reading
FAQ
Tirzepatide — Common Questions
What is Tirzepatide?
Dual GIP/GLP-1 receptor agonist for advanced metabolic research. Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. It represents a first-in-class approach to metabolic research by targeting two incretin recep… It is supplied for laboratory research use only.
What is the Tirzepatide dosage used in research?
Published research uses varying doses depending on the model and endpoint. EvoPeak supplies 5 mg and 10 mg and 15 mg vials. All dosage information is for research reference only and does not constitute recommendations.
What are the side effects of Tirzepatide?
Side effect profiles in published research depend on dose, route, and model system. Consult primary literature for compound-specific findings. All information is drawn from research contexts, not personal use.
Can I buy Tirzepatide in Australia?
Yes. EvoPeak supplies research-grade Tirzepatide to Australian researchers with HPLC/MS verification, batch-specific COA documentation, and domestic shipping. Products are for laboratory research use only.
How do I get Tirzepatide in Australia?
Order from the EvoPeak shop page, select your vial size, review the COA, and checkout with local Australian fulfilment.
How do I reconstitute Tirzepatide?
Tirzepatide is supplied as lyophilised powder. Reconstitute with bacteriostatic water, inject diluent slowly down the vial wall without shaking, and store at 2–8°C once reconstituted. Bacteriostatic water is available from EvoPeak.
What purity standard does EvoPeak Tirzepatide meet?
Every batch undergoes HPLC purity analysis (targeting >99%), mass spectrometry identity verification, and endotoxin screening. Batch-specific COAs are available on the product page.
Is tirzepatide peptide the same as Dual GIP/GLP-1 Receptor Agonist (Mounjaro analogue)?
Tirzepatide is also known as Dual GIP/GLP-1 Receptor Agonist (Mounjaro analogue). Both refer to the same research compound supplied by EvoPeak.
Related compounds
Explore related research peptides
Ready to order Tirzepatide?
Third-party HPLC/MS tested with batch-specific COA documentation. Shipped from Australia for laboratory research use only.